| Literature DB >> 27681434 |
Sabina Sangaletti1, Claudio Tripodo2, Alessandra Santangelo3, Nadia Castioni3, Paola Portararo3, Alessandro Gulino2, Laura Botti3, Mariella Parenza3, Barbara Cappetti3, Rosaria Orlandi4, Elda Tagliabue4, Claudia Chiodoni3, Mario P Colombo5.
Abstract
The extracellular matrix (ECM) contributes to the biological and clinical heterogeneity of breast cancer, and different prognostic groups can be identified according to specific ECM signatures. In high-grade, but not low-grade, tumors, an ECM signature characterized by high SPARC expression (ECM3) identifies tumors with increased epithelial-to-mesenchymal transition (EMT), reduced treatment response, and poor prognosis. To better understand how this ECM3 signature is contributing to tumorigenesis, we expressed SPARC in isogenic cell lines and found that SPARC overexpression in tumor cells reduces their growth rate and induces EMT. SPARC expression also results in the formation of a highly immunosuppressive microenvironment, composed by infiltrating T regulatory cells, mast cells, and myeloid-derived suppressor cells (MDSCs). The ability of SPARC to induce EMT depended on the localization and suppressive function of myeloid cells, and inhibition of the suppressive function MDSCs by administration of aminobisphosphonates could revert EMT, rendering SPARC-overexpressing tumor cells sensitive to Doxil. We conclude that that SPARC is regulating the interplay between MDSCs and the ECM to drive the induction of EMT in tumor cells.Entities:
Keywords: Breast cancer; COX-2; CXCL12; ECM; EMT; G-CSF; GM-CSF; MDSC; SPARC; aminobisphosphonates; cyclooxygenase-2; epithelial to mesenchymal transition; extracellular matrix; granulocyte colony-stimulating factor; granulocyte-macrophage colony-stimulating factor; myeloid-derived suppressor cells
Mesh:
Substances:
Year: 2016 PMID: 27681434 DOI: 10.1016/j.celrep.2016.08.075
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423